iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it will present clinical and preclinical data on two pipeline assets, IOA-244 and IOA-289, at the European Society of Medical Oncology’s Immuno-Oncology Congress taking place in, Switzerland and virtually.
Also Read: Invistics Enhances Drug Diversion Detection Software for Hospitals and Health Systems
IOA-244 is a novel phosphoinositide 3-kinase delta inhibitor with an unprecedented preclinical and clinical profile currently being investigated in Part B of the DIONE-01 trial. DIONE-01 is a two-part, first-in-human dose study evaluating IOA-244 in solid tumors and hematologic malignancies. Data from the first part of the study will be presented at ESMO-IO via a poster entitled “First-in-human, pharmacokinetic and pharmacodynamic study of IOA-244, a phosphoinositide 3-kinase delta inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma”.
IOA-289 will be the first autotaxin inhibitor to be clinically investigated in oncology. It is currently being evaluated in healthy volunteers as a preparatory study to a subsequent Phase I clinical study in pancreatic cancer. The poster presentation at ESMO-IO is entitled “Translating a novel autotaxin inhibitor from preclinical proof of concept in pancreatic cancer to a biomarker response in human subjects”.
iOnctura SA is clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface. iOnctura’s best-in-class drug development programs combine immune-mediated and direct anti-tumour activity to deliver molecules with superior clinical efficacy and safety in oncology.Its lead program, IOA-244 is the only semi-allosteric PI3Kdelta specific, orally dosed, small molecule inhibitor that is being developed in solid and hematological malignancies to address tumor and stroma induced immune suppression. IOA-244 is currently in Part B of a Phase 1 study. iOnctura’s second program, IOA-289, is an oral small molecule that inhibits the cross-talk between the tumor and its stroma and is in a Phase 1 clinical study. iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.